When: Sept 16-17 FOMC passes without hawkish surprise

Then: Execute final 25% reserve tranche

HOLD into FOMC; limit order to BUY at $617-$622 sized at half intended tranche, 3% portfolio cap, stop at $578

• PEG of 0.86 at a 28% grower is attractive on a fundamental basis
• Three consecutive failed breakout attempts in six months (Jul 1: $628, May 27: $634, Apr 17: $690) suggest higher base rate of failure
• Operating margin compressed 970 bps from 40.6% to 30.9% in single quarter; G&A more than doubled; R&D surged 30%+
• Balance sheet transformed from fortress to leveraged infrastructure: Net PPE up $87B ($162B to $249B), total debt doubled ($49B to $112B), net debt at $68B
• Beta of 1.24 means downside overshoot matches upside overshoot in macro tail-risk environment
• Insider selling corroborates with WSB bearish pocket, options-implied downside skew, and capex-driven FCF compression
• Trader's plan is internally contradictory: initiates at $652 while identifying $617-$622 as high-conviction add zone
• Risk-adjusted entry improves 60-70 basis points by waiting for pullback without changing thesis

→ vs aggressive: Beta of 1.24 is not asymmetric upside - it's symmetric exposure that overshoots to downside in hot CPI, 93% Polymarket no-cut probability, 70% rate hike odds environment

→ vs aggressive: Net PPE build of $87B and European bond roadshow show internal cash flow no longer self-funding; balance sheet is being converted from fortress to leveraged play

→ vs aggressive: 970 bps margin compression is not 'deliberate reinvestment' to look past - it's a potential inflection point toward structural deterioration, not proof of 2027-2028 expansion

→ vs aggressive: Initiating at $652 (high of range) while identifying $617-$622 as high-conviction zone is backwards execution; better risk-adjusted entry is simply to wait

→ vs aggressive: 4-5% position cap is upper bound of prudent, not lower bound; should tighten to 2-3% given beta 1.24, hawkish FOMC in 7 days, and 70% adverse catalyst probability

→ vs aggressive: Calling WSB bearish pocket a 'contrary indicator' because retail is 'consistently wrong on quality compounders' is not a risk framework - it's momentum positioning; the bearish case here is corroborated by capex, FCF, insider, and options data

Initiate 25-30% tranche at current levels near $648; reserve 70-75% for $617-$622 pullback or post-FOMC confirmation. Cap total exposure at 3-3.5%. Stop at $578. Require successful retest of 50-day SMA at $600.90 before scaling to full size.

• Structural bull case intact: PEG below 1, 18.5 forward P/E, dominant ad platform, massive AI capex cycle
• Recommends smaller first tranche of 25-30% of intended position at current levels
• Reserve 70-75% of position for either $617-$622 pullback zone or post-FOMC confirmation
• Cap total exposure at 3-3.5% until FOMC clarity and breakout confirmation
• Stop at $578 represents 7-11% loss depending on entry
• Beta of 1.24 is asymmetric risk in hawkish regime—not just upside amplifier
• Third failed breakout in six months is a real pattern; current setup has more technical confirmation than prior attempts but pattern deserves respect
• 970 bps operating margin compression is ambiguous—could be Q2 noise from G&A spike or start of structural cost regime
• Forward P/E of 18.5, PEG below 1, 28% revenue growth, fortress balance sheet, 3 billion users justify meaningful exposure but not at aggressive sizing
• If META breaks below 50-day SMA at $600.90 on a closing basis, breakout thesis is invalidated and trade should be reassessed
• Conservative analyst's 2-3% cap is too tight for a high-quality compounder; 4-5% is too generous given macro and technical risk
• Insider selling cited by conservative analyst is weak evidence—could be 10b5-1 plan execution set up months ago

→ vs aggressive: WSB-as-contrary-indicator is not methodology; retail bearishness doesn't auto-flip to a buy signal when the capex concerns, FCF crater, insider activity, and options skew are well-reasoned

→ vs aggressive: Beta of 1.24 in a hawkish Fed regime amplifies downside more than upside; treating it as only an upside accelerant ignores the asymmetry at the moment it's most relevant

→ vs aggressive: Failed breakout pattern is real—three breakouts in six months that all faded; 'this time is different' due to golden cross and volume confirmation is the canonical argument made before every failed breakout

→ vs aggressive: 970 bps operating margin compression cannot be cleanly framed as either 'deliberate reinvestment' or 'structural deterioration'—it's genuinely ambiguous from one quarter's data

→ vs conservative: Conservative analyst conflates all four failed breakouts as equivalent; Sep 9 breakout on 35.9M shares reclaiming the 200-day SMA with confirmed golden cross is materially different from Jul 1 and May 27 single-day air pockets that didn't reclaim key moving averages

→ vs conservative: Waiting for $617-$622 is contingent on a pullback actually happening; if dovish FOMC surprise squeezes stock to $680, the conservative plan never triggers and the structural thesis gets left on the table indefinitely

→ vs conservative: 2-3% position cap is overly tight for a high-quality compounder with 18.5 forward P/E, PEG below 1, 28% revenue growth, fortress balance sheet, and 3 billion users—this is not speculative biotech

→ vs conservative: Insider selling is low-quality evidence; if removed entirely from the bear case, would the capex concerns and FCF compression stand on their own? Yes, so insider activity is a minor corroborator, not a load-bearing pillar